Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

That's because Novartis hasn't taken the option yet. Institutions and big funds won't commit bit capital until it is final. In other words they will not enter until it is announced that Novartis takes the option to license Emricasan.

Once that happens in Q2 after CNAT starts the phase 2b LC trial then we will see early teens in stock price IMO once funds start loading up. Again, that won't happen until Novartis takes the option to license.